BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28257290)

  • 41. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
    Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
    BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S43-9. PubMed ID: 23519304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India.
    Joshi S; Muwonge R; Kulkarni V; Mandolkar M; Lucas E; Pujari S; Sankaranarayanan R; Basu P
    Int J Cancer; 2023 Jan; 152(2):249-258. PubMed ID: 35852007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.
    Dillner J; Rebolj M; Birembaut P; Petry KU; Szarewski A; Munk C; de Sanjose S; Naucler P; Lloveras B; Kjaer S; Cuzick J; van Ballegooijen M; Clavel C; Iftner T;
    BMJ; 2008 Oct; 337():a1754. PubMed ID: 18852164
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Repeat cytology and human papillomavirus screening strategies in detecting preinvasive cervical lesions.
    Li K; Yin R
    Medicine (Baltimore); 2015 Feb; 94(5):e435. PubMed ID: 25654377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Follow-up findings for women with human papillomavirus-positive and atypical squamous cells of undetermined significance screening test results in a large women's hospital practice.
    Armah H; Austin RM; Dabbs D; Zhao C
    Arch Pathol Lab Med; 2009 Sep; 133(9):1426-30. PubMed ID: 19722749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reflex Human Papillomavirus Test Results as an Option for the Management of Korean Women With Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion.
    Ryu KJ; Lee S; Min KJ; Kim JW; Hong JH; Song JY; Lee JK; Lee NW
    Oncologist; 2015 Jun; 20(6):635-9. PubMed ID: 25964305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Co-infection with trichomonas vaginalis increases the risk of cervical intraepithelial neoplasia grade 2-3 among HPV16 positive female: a large population-based study.
    Yang M; Li L; Jiang C; Qin X; Zhou M; Mao X; Xing H
    BMC Infect Dis; 2020 Sep; 20(1):642. PubMed ID: 32873233
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
    Bokan T; Ivanus U; Jerman T; Takac I; Arko D
    Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy.
    Passamonti B; Gustinucci D; Giorgi Rossi P; Cesarini E; Bulletti S; Carlani A; Martinelli N; Broccolini M; D'Angelo V; D'Amico MR; Di Dato E; Galeazzi P; Malaspina M; Spita N; Tintori B; Giaimo MD
    J Med Screen; 2017 Sep; 24(3):153-162. PubMed ID: 27614992
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atypical squamous cells of undetermined significance, human papillomavirus, and cervical intraepithelial neoplasia 2 or 3 in adolescents: ASC-US, age, and high-grade cervical neoplasia.
    Boardman LA; Weitzen S; Stanko C
    J Low Genit Tract Dis; 2006 Jul; 10(3):140-5. PubMed ID: 16829752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.
    Rodríguez AC; Schiffman M; Herrero R; Hildesheim A; Bratti C; Sherman ME; Solomon D; Guillén D; Alfaro M; Morales J; Hutchinson M; Katki H; Cheung L; Wacholder S; Burk RD
    J Natl Cancer Inst; 2010 Mar; 102(5):315-24. PubMed ID: 20157096
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
    Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
    PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.